{"id":"clomethiazole","rwe":[{"pmid":"41706162","year":"2026","title":"Management of insomnia in inpatient psychiatric care: a clinical practice evaluation.","finding":"","journal":"European archives of psychiatry and clinical neuroscience","studyType":"Clinical Study"},{"pmid":"41092501","year":"2026","title":"Detection and in silico evaluation of undeclared venlafaxine and clomethiazole in a counterfeit herbal product marketed for alcohol withdrawal syndrome.","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"},{"pmid":"40906254","year":"2026","title":"Pharmacotherapy for psychiatric inpatients with alcohol use disorder or acute intoxication: results from an observational pharmacovigilance program-status and changes between 2000 and 2016.","finding":"","journal":"Journal of neural transmission (Vienna, Austria : 1996)","studyType":"Clinical Study"},{"pmid":"40192654","year":"2025","title":"The role of cytochrome P4502E1 in ethanol mediated diseases: a narrative update.","finding":"","journal":"Alcohol and alcoholism (Oxford, Oxfordshire)","studyType":"Clinical Study"},{"pmid":"39613826","year":"2024","title":"Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"}],"tags":[{"label":"clomethiazole","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"GABA-A receptor alpha-1/beta-3/gamma-2","category":"target"},{"label":"GABRA1","category":"gene"},{"label":"GABRB3","category":"gene"},{"label":"GABRG2","category":"gene"},{"label":"N05CM02","category":"atc"},{"label":"Active","category":"status"},{"label":"Alcohol withdrawal syndrome","category":"indication"},{"label":"Insomnia","category":"indication"},{"label":"Anticonvulsants","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"GABA Agents","category":"pharmacology"},{"label":"GABA Modulators","category":"pharmacology"},{"label":"Hypnotics and Sedatives","category":"pharmacology"},{"label":"Neuroprotective Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":72.185,"date":"","count":58,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 58 times (LLR=72)"},{"llr":62.165,"date":"","count":13,"signal":"Drug withdrawal convulsions","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=62)"},{"llr":60.049,"date":"","count":30,"signal":"Depressed level of consciousness","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=60)"},{"llr":51.695,"date":"","count":9,"signal":"Vascular encephalopathy","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=52)"},{"llr":46.572,"date":"","count":8,"signal":"Joint hyperextension","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=47)"},{"llr":43.002,"date":"","count":10,"signal":"Cogwheel rigidity","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=43)"},{"llr":42.823,"date":"","count":11,"signal":"Persecutory delusion","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=43)"},{"llr":40.984,"date":"","count":11,"signal":"Subileus","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=41)"},{"llr":40.518,"date":"","count":18,"signal":"Toxic epidermal necrolysis","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=41)"}],"commonSideEffects":[{"effect":"Drug interaction","drugRate":"LLR 72","severity":"common"},{"effect":"Drug withdrawal convulsions","drugRate":"LLR 62","severity":"common"},{"effect":"Depressed level of consciousness","drugRate":"LLR 60","severity":"common"},{"effect":"Vascular encephalopathy","drugRate":"LLR 52","severity":"common"},{"effect":"Joint hyperextension","drugRate":"LLR 47","severity":"common"},{"effect":"Cogwheel rigidity","drugRate":"LLR 43","severity":"common"},{"effect":"Persecutory delusion","drugRate":"LLR 43","severity":"common"},{"effect":"Subileus","drugRate":"LLR 41","severity":"common"},{"effect":"Toxic epidermal necrolysis","drugRate":"LLR 41","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"emineurina","offLabel":[],"synonyms":["chlormethiazole","clomethiazole","chlorethiazol","chlorethiazole","chlormethiazol","clomethiazolum","distraneurin","emineurina","chlormethiazole hydrochloride","chlormethiazole HCl","clomethiazole edisilate"],"timeline":[{"date":"1981-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1981-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Emineurina","ecosystem":[{"indication":"Alcohol withdrawal syndrome","otherDrugs":[{"name":"chlordiazepoxide","slug":"chlordiazepoxide","company":"Valeant Pharm Intl"},{"name":"clorazepate","slug":"clorazepate","company":"Recordati Rare"},{"name":"diazepam","slug":"diazepam","company":"Roche"}],"globalPrevalence":null},{"indication":"Insomnia","otherDrugs":[{"name":"amobarbital","slug":"amobarbital","company":""},{"name":"choline","slug":"choline","company":""},{"name":"daridorexant","slug":"daridorexant","company":"Idorsia Pharmaceuticals Ltd"},{"name":"diphenhydramine","slug":"diphenhydramine","company":"Mcneil Cons"}],"globalPrevalence":750000000}],"mechanism":{"target":"GABA-A receptor alpha-1/beta-3/gamma-2","targets":[{"gene":"GABRA1","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-1"},{"gene":"GABRB3","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit beta-3"},{"gene":"GABRG2","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit gamma-2"}],"modality":"Small Molecule","drugClass":"clomethiazole","explanation":"Imagine your brain is like a busy city with many cars racing around. GABA is like a traffic cop that helps slow down the traffic. Emineurina helps the traffic cop work more effectively, reducing the noise and chaos in the brain.","oneSentence":"Emineurina works by enhancing the activity of the neurotransmitter GABA, which helps to calm excessive brain activity.","technicalDetail":"Emineurina acts as a positive allosteric modulator of the GABA-A receptor, increasing the frequency of chloride channel opening and enhancing the inhibitory effects of GABA on neuronal excitability."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/602","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CLOMETHIAZOLE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOMETHIAZOLE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:11:05.806590","biosimilars":[],"competitors":[{"drugName":"scopolamine","drugSlug":"scopolamine","fdaApproval":"1979-12-31","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"propiomazine","drugSlug":"propiomazine","fdaApproval":"1960-12-05","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"triclofos","drugSlug":"triclofos","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ethchlorvynol","drugSlug":"ethchlorvynol","fdaApproval":"1961-05-10","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dexmedetomidine","drugSlug":"dexmedetomidine","fdaApproval":"1999-12-17","patentExpiry":"Jun 26, 2039","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"suvorexant","drugSlug":"suvorexant","fdaApproval":"2014-08-13","patentExpiry":"Nov 20, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lemborexant","drugSlug":"lemborexant","fdaApproval":"2019-12-20","patentExpiry":"Sep 20, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"clomethiazole","indications":{"approved":[{"name":"Alcohol withdrawal syndrome","source":"DrugCentral","snomedId":191480000,"regulator":"FDA"},{"name":"Insomnia","source":"DrugCentral","snomedId":193462001,"regulator":"FDA","usPrevalence":70000000,"globalPrevalence":750000000,"prevalenceMethod":"curated","prevalenceSource":"Sleep Medicine Reviews, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"scopolamine","brandName":"scopolamine","genericName":"scopolamine","approvalYear":"1979","relationship":"same-class"},{"drugId":"propiomazine","brandName":"propiomazine","genericName":"propiomazine","approvalYear":"1960","relationship":"same-class"},{"drugId":"triclofos","brandName":"triclofos","genericName":"triclofos","approvalYear":"","relationship":"same-class"},{"drugId":"ethchlorvynol","brandName":"ethchlorvynol","genericName":"ethchlorvynol","approvalYear":"1961","relationship":"same-class"},{"drugId":"dexmedetomidine","brandName":"dexmedetomidine","genericName":"dexmedetomidine","approvalYear":"1999","relationship":"same-class"},{"drugId":"suvorexant","brandName":"suvorexant","genericName":"suvorexant","approvalYear":"2014","relationship":"same-class"},{"drugId":"lemborexant","brandName":"lemborexant","genericName":"lemborexant","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167093","NDDF":"003691","UNII":"0C5DBZ19HV","CHEBI":"CHEBI:92875","INN_ID":"1717","RXNORM":"20802","UMLSCUI":"C0008221","ChEMBL_ID":"CHEMBL315795","KEGG_DRUG":"D07330","DRUGBANK_ID":"DB06470","PUBCHEM_CID":"10783","SNOMEDCT_US":"354039005","MESH_DESCRIPTOR_UI":"D002719"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.5 hours","clearance":"33.0 mL/min/kg","bioavailability":"25%","fractionUnbound":"0.36%","volumeOfDistribution":"6.6 L/kg"},"publicationCount":228,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05CM02","allCodes":["N05CM02","N05CX04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 18","pmid":"41706162","title":"Management of insomnia in inpatient psychiatric care: a clinical practice evaluation.","journal":"European archives of psychiatry and clinical neuroscience"},{"date":"2026 Jan 15","pmid":"41092501","title":"Detection and in silico evaluation of undeclared venlafaxine and clomethiazole in a counterfeit herbal product marketed for alcohol withdrawal syndrome.","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"2026 Mar","pmid":"40906254","title":"Pharmacotherapy for psychiatric inpatients with alcohol use disorder or acute intoxication: results from an observational pharmacovigilance program-status and changes between 2000 and 2016.","journal":"Journal of neural transmission (Vienna, Austria : 1996)"},{"date":"2025 Mar 25","pmid":"40192654","title":"The role of cytochrome P4502E1 in ethanol mediated diseases: a narrative update.","journal":"Alcohol and alcoholism (Oxford, Oxfordshire)"},{"date":"2024 Nov 29","pmid":"39613826","title":"Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system.","journal":"Scientific reports"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Emineurina (Clomethiazole) is a small molecule drug that targets the GABA-A receptor alpha-1/beta-3/gamma-2 subunit, classified as a clomethiazole. It is used to treat alcohol withdrawal syndrome and insomnia. The commercial status of Emineurina is unknown, and it is not FDA-approved. Key safety considerations include its short half-life of 4.5 hours and moderate bioavailability of 25%. Further research is needed to determine its patent status and generic availability.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1981-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}